Trial Profile

A 2-part Trial Comparing Overall Survival of Patients With Metastatic Ewing's Sarcoma Treated With Vigil Versus Gemcitabine and Docetaxel and to Determine Safety Profile of Vigil in Combination With Irinotecan and Temozolomide

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 26 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bi-shRNAfurin-GM-CSF-loaded tumour cell vaccine (Primary) ; Docetaxel; Gemcitabine; Irinotecan; Irinotecan; Pegfilgrastim; Temozolomide
Indications Ewing's sarcoma
Focus Adverse reactions
Sponsors Gradalis

03 Feb 2021 Status changed from active, no longer recruiting to completed.
20 Jul 2020 Planned End Date changed from 31 Dec 2020 to 31 Dec 2021.
20 Jul 2020 Planned primary completion date changed from 1 Dec 2019 to 31 Dec 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com